NASDAQ:PRAX Praxis Precision Medicines (PRAX) Stock Price, News & Analysis → Breaking News: Elon Musk Invents New Type of A.I. (Shocking) (From InvestorPlace) (Ad) Free PRAX Stock Alerts $45.39 +0.18 (+0.40%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$44.37▼$47.0850-Day Range$44.00▼$62.1852-Week Range$12.45▼$67.21Volume273,439 shsAverage Volume264,568 shsMarket Capitalization$776.62 millionP/E RatioN/ADividend YieldN/APrice Target$105.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Praxis Precision Medicines alerts: Email Address Praxis Precision Medicines MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside133.1% Upside$105.80 Price TargetShort InterestBearish5.06% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.20Based on 33 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($10.13) to ($9.86) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.52 out of 5 starsMedical Sector706th out of 919 stocksPharmaceutical Preparations Industry327th out of 422 stocks 3.4 Analyst's Opinion Consensus RatingPraxis Precision Medicines has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoveragePraxis Precision Medicines has only been the subject of 4 research reports in the past 90 days.Read more about Praxis Precision Medicines' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.06% of the float of Praxis Precision Medicines has been sold short.Short Interest Ratio / Days to CoverPraxis Precision Medicines has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Praxis Precision Medicines has recently increased by 7.92%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldPraxis Precision Medicines does not currently pay a dividend.Dividend GrowthPraxis Precision Medicines does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PRAX. Previous Next 2.3 News and Social Media Coverage News SentimentPraxis Precision Medicines has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.48 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 33 news articles for Praxis Precision Medicines this week, compared to 3 articles on an average week.Search Interest12 people have searched for PRAX on MarketBeat in the last 30 days. This is an increase of 9% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Praxis Precision Medicines to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Praxis Precision Medicines insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.70% of the stock of Praxis Precision Medicines is held by insiders.Percentage Held by Institutions67.84% of the stock of Praxis Precision Medicines is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Praxis Precision Medicines' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Praxis Precision Medicines are expected to grow in the coming year, from ($10.13) to ($9.86) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Praxis Precision Medicines is -2.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Praxis Precision Medicines is -2.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPraxis Precision Medicines has a P/B Ratio of 3.38. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Praxis Precision Medicines' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street veteran, Eric Fry… This mind-blowing new technology could be bigger than the iPhone.Click here for the full story… About Praxis Precision Medicines Stock (NASDAQ:PRAX)Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.Read More PRAX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PRAX Stock News HeadlinesMay 18 at 5:45 AM | americanbankingnews.comTruist Financial Reiterates "Buy" Rating for Praxis Precision Medicines (NASDAQ:PRAX)May 17 at 8:00 AM | globenewswire.comPraxis Precision Medicines to Participate in Upcoming Investor ConferencesMay 16 at 6:13 PM | markets.businessinsider.comCritical Insights From Praxis Precision Medicine Analyst Ratings: What You Need To KnowMay 16 at 8:12 AM | markets.businessinsider.comBuy Rating Backed by Robust Pipeline and Market Opportunity for Praxis Precision MedicinesMay 16 at 6:56 AM | americanbankingnews.comHC Wainwright Analysts Raise Earnings Estimates for Praxis Precision Medicines, Inc. (NASDAQ:PRAX)May 16 at 4:28 AM | americanbankingnews.comPraxis Precision Medicines (NASDAQ:PRAX) Stock Rating Reaffirmed by HC WainwrightMay 16 at 3:02 AM | americanbankingnews.comPraxis Precision Medicines, Inc. Forecasted to Earn Q1 2025 Earnings of ($1.89) Per Share (NASDAQ:PRAX)May 16 at 1:26 AM | americanbankingnews.comWedbush Research Analysts Cut Earnings Estimates for Praxis Precision Medicines, Inc. (NASDAQ:PRAX)May 14, 2024 | finance.yahoo.comWe're Hopeful That Praxis Precision Medicines (NASDAQ:PRAX) Will Use Its Cash WiselyMay 13, 2024 | marketwatch.comPraxis Precision Medicines Shares Drop 5% After 1Q Results Miss ExpectationsMay 13, 2024 | finanznachrichten.dePraxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial ResultsMay 13, 2024 | msn.comPraxis Precision Medicines GAAP EPS of -$2.84 misses by $0.75, revenue of $0.43M misses by $1.33MMay 13, 2024 | globenewswire.comPraxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial ResultsMay 13, 2024 | americanbankingnews.comComparing LifeVantage (NASDAQ:LFVN) & Praxis Precision Medicines (NASDAQ:PRAX)May 12, 2024 | markets.businessinsider.comPraxis Precision Medicines is about to announce earnings — here's what Wall Street expectsMay 12, 2024 | americanbankingnews.comPraxis Precision Medicines (PRAX) Set to Announce Quarterly Earnings on MondayMay 10, 2024 | globenewswire.comPraxis Precision Medicines to Report First Quarter 2024 Financial Results on Monday, May 13, 2024May 3, 2024 | globenewswire.comPraxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 1, 2024 | msn.comBaird Initiates Coverage of Praxis Precision Medicines (PRAX) with Outperform RecommendationApril 30, 2024 | msn.comGoldman Sachs revamps "high-quality" stock picks listApril 30, 2024 | msn.comBankrupt national retailer pins hopes on popular new serviceApril 26, 2024 | tmcnet.comMedaptus and Banner Health Partner to Revolutionize Charge Processing with Charge Pro: Beyond Automation to Enhanced Efficiency and PrecisionApril 26, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Hookipa Pharma (HOOK), Praxis Precision Medicines (PRAX) and Blueprint Medicines (BPMC)April 22, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: BioCryst (BCRX), Ironwood Pharma (IRWD)April 17, 2024 | msn.comWhy an ALS Drug Was Pulled From the MarketSee More Headlines Receive PRAX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Praxis Precision Medicines and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/05/2024Today5/18/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PRAX CUSIPN/A CIK1689548 Webwww.praxismedicines.com Phone617-300-8460FaxN/AEmployees82Year FoundedN/APrice Target and Rating Average Stock Price Target$105.80 High Stock Price Target$150.00 Low Stock Price Target$29.00 Potential Upside/Downside+133.1%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($15.8550) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-123,280,000.00 Net Margins-5,711.85% Pretax Margin-5,711.85% Return on Equity-101.99% Return on Assets-86.68% Debt Debt-to-Equity RatioN/A Current Ratio11.27 Quick Ratio5.39 Sales & Book Value Annual Sales$2.45 million Price / Sales316.99 Cash FlowN/A Price / Cash FlowN/A Book Value$13.43 per share Price / Book3.38Miscellaneous Outstanding Shares17,110,000Free Float16,646,000Market Cap$776.62 million OptionableOptionable Beta2.87 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Marcio Silva De'Souza M.B.A. (Age 44)President, CEO & Director Comp: $1.18MMr. Timothy Edwin Kelly (Age 50)CFO & Treasurer Comp: $691.58kMr. Alex Nemiroff J.D. (Age 44)General Counsel & Secretary Comp: $577.34kDr. Steven Petrou B.Sc. (Hons.)Ph.D., Co-Founder & Chief Scientific OfficerLauren MastrocolaVP of Finance & Principal Accounting OfficerDr. Karl Hansen Ph.D.Chief Technical Operations OfficerAlex KaneVP of Investor Relations & Corporate CommunicationsMs. Kelly McCueChief People OfficerMs. Alyssa J. S. Wyant (Age 49)Chief Regulatory & Quality Officer Ms. Megan T. Sniecinski (Age 42)Chief Business Officer More ExecutivesKey CompetitorsDisc MedicineNASDAQ:IRONALX OncologyNASDAQ:ALXOLongboard PharmaceuticalsNASDAQ:LBPHIntercept PharmaceuticalsNASDAQ:ICPTEvolusNASDAQ:EOLSView All CompetitorsInsiders & InstitutionsRA Capital Management L.P.Bought 828,380 shares on 5/17/2024Ownership: 4.841%Kingdon Capital Management L.L.C.Bought 3,335 shares on 5/16/2024Ownership: 2.046%Janus Henderson Group PLCBought 310,059 shares on 5/16/2024Ownership: 1.812%Jacobs Levy Equity Management Inc.Sold 14,940 shares on 5/16/2024Ownership: 0.301%Price T Rowe Associates Inc. MDBought 535,999 shares on 5/15/2024Ownership: 3.133%View All Insider TransactionsView All Institutional Transactions PRAX Stock Analysis - Frequently Asked Questions Should I buy or sell Praxis Precision Medicines stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Praxis Precision Medicines in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" PRAX shares. View PRAX analyst ratings or view top-rated stocks. What is Praxis Precision Medicines' stock price target for 2024? 5 brokers have issued twelve-month target prices for Praxis Precision Medicines' stock. Their PRAX share price targets range from $29.00 to $150.00. On average, they anticipate the company's stock price to reach $105.80 in the next year. This suggests a possible upside of 133.1% from the stock's current price. View analysts price targets for PRAX or view top-rated stocks among Wall Street analysts. How have PRAX shares performed in 2024? Praxis Precision Medicines' stock was trading at $22.28 on January 1st, 2024. Since then, PRAX stock has increased by 103.7% and is now trading at $45.39. View the best growth stocks for 2024 here. When is Praxis Precision Medicines' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024. View our PRAX earnings forecast. How were Praxis Precision Medicines' earnings last quarter? Praxis Precision Medicines, Inc. (NASDAQ:PRAX) released its quarterly earnings results on Tuesday, March, 5th. The company reported ($2.97) EPS for the quarter, beating analysts' consensus estimates of ($3.05) by $0.08. The business earned $0.52 million during the quarter, compared to analysts' expectations of $0.30 million. Praxis Precision Medicines had a negative net margin of 5,711.85% and a negative trailing twelve-month return on equity of 101.99%. What ETF holds Praxis Precision Medicines' stock? Invesco Dorsey Wright Healthcare Momentum ETF holds 24,700 shares of PRAX stock, representing 0.81% of its portfolio. When did Praxis Precision Medicines' stock split? Praxis Precision Medicines shares reverse split on the morning of Wednesday, November 29th 2023. The 1-15 reverse split was announced on Wednesday, November 29th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 29th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Praxis Precision Medicines IPO? Praxis Precision Medicines (PRAX) raised $126 million in an initial public offering on Friday, October 16th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Cowen, Evercore ISI, Piper Sandler and Wedbush PacGrow served as the underwriters for the IPO and Blackstone Capital Markets was co-manager. Who are Praxis Precision Medicines' major shareholders? Praxis Precision Medicines' stock is owned by a number of institutional and retail investors. Top institutional shareholders include RA Capital Management L.P. (4.84%), Vanguard Group Inc. (4.35%), Price T Rowe Associates Inc. MD (3.13%), Kingdon Capital Management L.L.C. (2.05%), Janus Henderson Group PLC (1.81%) and Acadian Asset Management LLC (0.48%). Insiders that own company stock include Alex Nemiroff, Dean J Mitchell, Jill Desimone, Lauren Mastrocola, Marcio Souza, Parallel Master Fund LP Bsof and Timothy Edwin Kelly. View institutional ownership trends. How do I buy shares of Praxis Precision Medicines? Shares of PRAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PRAX) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingDems have chosen Biden replacement?Paradigm PressThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaA letter is coming from the "Bureau of the Fiscal Service".Stansberry ResearchCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlaceForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsNext President (Not Trump. Not Biden.)The Freeport Society4 Cryptos BETTER than BitcoinTrue Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Praxis Precision Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.